References
- Carey LA, Perou CM, Livasy CA, et al (2006). Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 295, 2492-502. https://doi.org/10.1001/jama.295.21.2492
- Goldhirsch A, Ingle JN, Gelber RD, et al (2009). Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol, 20, 1319-29. https://doi.org/10.1093/annonc/mdp322
- Goldhirsch A, Wood WC, Coates AS, et al (2011). Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol, 22, 1736-47. https://doi.org/10.1093/annonc/mdr304
- Hudis CA, Gianni L (2011). Triple-negative breast cancer: an unmet medical need. Oncologist, 16, 1-11.
- Ihemelandu CU, Naab TJ, Mezghebe HM, et al (2008). Treatment and survival outcome for molecular breast cancer subtypes in black women. Ann Surg, 247, 463-9. https://doi.org/10.1097/SLA.0b013e31815d744a
- Kostopoulou E, Vageli D, Kaisaridou D, et al (2007) Comparative evaluation of non-informative HER-2 immunoreactions (2+) in breast carcinomas with FISH, CISH and QRT-PCR. Breast, 16, 615-24. https://doi.org/10.1016/j.breast.2007.05.008
- Kyndi M, Sorensen FB, Knudsen H, et al (2008). Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol, 26, 1419-26. https://doi.org/10.1200/JCO.2007.14.5565
- Nguyen PL, Taghian AG, Katz MS, et al (2008). Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol, 26, 2373-8. https://doi.org/10.1200/JCO.2007.14.4287
- Sorlie T, Perou CM, Tibshirani R, et al (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA, 98, 10869-74. https://doi.org/10.1073/pnas.191367098
- Sorlie T, Tibshirani R, Parker J, et al (2003). Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA, 100, 8418-23. https://doi.org/10.1073/pnas.0932692100
- Sotiriou C, Neo SY, McShane LM, et al (2003). Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA, 100, 10393-8. https://doi.org/10.1073/pnas.1732912100
- Voduc KD, Cheang MC, Tyldesley S, et al (2010). Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol, 28, 1684-91. https://doi.org/10.1200/JCO.2009.24.9284
- Wiechmann L, Sampson M, Stempel M, et al (2009). Presenting features of breast cancer differ by molecular subtype. Ann Surg Oncol, 16, 2705-10. https://doi.org/10.1245/s10434-009-0606-2
Cited by
- Association of Immunohistochemically Defined Molecular Subtypes with Clinical Response to Presurgical Chemotherapy in Patients with Advanced Breast Cancer vol.14, pp.5, 2013, https://doi.org/10.7314/APJCP.2013.14.5.3223
- SLC35B2 Expression is Associated with a Poor Prognosis of Invasive Ductal Breast Carcinoma vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6065
- Clinicopathological Features of Indonesian Breast Cancers with Different Molecular Subtypes vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6109
- Development and Validation of a Breast Cancer Risk Prediction Model for Thai Women: A Cross-Sectional Study vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6811
- Clinicopathologic Features of Breast Carcinomas Classified by Biomarkers and Correlation with Microvessel Density and VEGF Expression: A Study from Thailand vol.15, pp.3, 2014, https://doi.org/10.7314/APJCP.2014.15.3.1187
- Survival Time and Molecular Subtypes of Breast Cancer after Radiotherapy in Thailand vol.15, pp.23, 2015, https://doi.org/10.7314/APJCP.2014.15.23.10505
- No Increase in Breast Cancer Risk in Japanese Women Taking Oral Contraceptives: a Case-Control Study Investigating Reproductive, Menstrual and Familial Risk Factors for Breast Cancer vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.3685
- Analysis of circulating microRNAs during adjuvant chemotherapy in patients with luminal A breast cancer vol.3, pp.4, 2015, https://doi.org/10.3892/mco.2015.567
- Patients’ preferences and willingness-to-pay for postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer treatments after failure of standard treatments vol.4, pp.1, 2015, https://doi.org/10.1186/s40064-015-1482-9
- Developing a risk prediction model for breast cancer: a Statistical Utility to Determine Affinity of Neoplasm (SUDAN-CA Breast) vol.22, pp.1, 2017, https://doi.org/10.1186/s40001-017-0277-6
- Significance of ERβ expression in different molecular subtypes of breast cancer vol.9, pp.1, 2014, https://doi.org/10.1186/1746-1596-9-20